Editas Medicine Inc. Common Stock (EDIT)

About EDIT

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develop…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

87

Website

www.editasmedicine.com/

Fundamentals

1-day range

$3.15$3.41

Market cap

$283.93M

P/E (trailing)

—

P/E (forward)

-4.20

EPS (trailing)

$-0.74

Dividend yield

—

Beta

2.02

Avg. volume

2.44M

Forecasts

9 analyst ratings

Editas Medicine Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• EDIT

  Editas Medicine Inc. Common Stock

  $3.15

  ▼ 4.55%
  Market cap $283.93MP/E —
  $1.66$4.54
• LCTX

  Lineage Cell Therapeutics Inc. Common Stock

  $1.11

  ▼ 4.31%
  Market cap $281.71MP/E —
  $1$2.09
• FATE

  Fate Therapeutics Inc. Common Stock

  $2.42

  ▼ 4.92%
  Market cap $290.23MP/E —
• SABS

  SAB Biotherapeutics Inc. Common Stock

  $3.79

  ▼ 3.56%
  Market cap $294.39MP/E 26.94
  $1.85$5.15
• NMRA

  Neumora Therapeutics Inc. Common Stock

  $1.38

  ▼ 6.76%
  Market cap $303.87MP/E —
  $0.83015$3.65
• AVXL

  Anavex Life Sciences Corp. Common Stock

  $2.98

  ▼ 4.79%
  Market cap $303.96MP/E —
  $2.26$10.4
• SRZN

  Surrozen Inc. Common Stock

  $22.42

  ▼ 6.62%
  Market cap $251.25MP/E —
  $10.73$35

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday
  Benzinga · 8/19/2026
• Editas Medicine (NASDAQ:EDIT) Beats Q2 Estimates, but One-Time Revenue Boost Masks Underlying Momentum
  ChartMill · 8/6/2026
• Editas Medicine Q2 EPS $(0.15) Beats $(0.27) Estimate, Sales $11.900M Beat $2.800M Estimate
  benzinga · 8/5/2026
• Editas Medicine Q2 EPS $(0.15) Beats $(0.27) Estimate, Sales $11.900M Beat $2.800M Estimate
  Benzinga · 8/5/2026

• Ellinor Patrick Thomas II · August 6, 2026 · Grant

  103.4K
• Amy Parison · August 3, 2026 · Sale

  678 @ $2.58
• Linda Burkly · July 28, 2026 · Sale

  4.9K @ $2.67
• Bernadette Connaughton · June 17, 2026 · Grant

  51.7K
• Scadden David · June 17, 2026 · Grant

  51.7K
• Levy Elliott M. · June 17, 2026 · Grant

  51.7K
• Jessica Hopfield · June 17, 2026 · Grant

  51.7K
• Andrew Hirsch · June 17, 2026 · Grant

  51.7K
• Amy Parison · June 3, 2026 · Sale

  464 @ $2.7
• Gilmore Neil O'Neill · June 3, 2026 · Sale

  15.4K @ $2.7
• Linda Burkly · June 3, 2026 · Sale

  731 @ $2.7
• Gilmore Neil O'Neill · March 12, 2026 · Grant

  1.02M
• Amy Parison · March 12, 2026 · Grant

  292.9K
• Linda Burkly · March 12, 2026 · Grant

  292.9K
• Gilmore Neil O'Neill · March 3, 2026 · Sale

  5.4K @ $2.02

Institutional Ownership

March 31, 2026

Total shares held

46.71M

Total value held

$109.73M

Institutional holders

203